.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,686,099

« Back to Dashboard

Details for Patent: 5,686,099

Title: Method and device for the release of drugs to the skin
Abstract:A method of increasing the adhesiveness of a shaped pressure sensitive adhesive, comprising adding an adhesiveness and drug release increasing amount of a clay to said adhesive prior to casting of the adhesive. A dermal composition comprising a drug, a pressure sensitive adhesive, an adhesiveness increasing amount of a clay and a solvent. A dermal composition comprising a drug, a multipolymer of ethylene vinyl acetate, an acrylic polymer, a natural or synthetic rubber and a clay, along with optional ingredients known for use in transdermal drug delivery systems.
Inventor(s): Sablotsky; Steven (Miami, FL), Gentile; Joseph A. (Plantation, FL)
Assignee: Noven Pharmaceuticals, Inc. (Miami, FL)
Filing Date:May 26, 1993
Application Number:08/067,001
Claims:1. A dermal composition comprising a mixture of 0.1 to 50 by dry weight of a drug, a pressure sensitive adhesive, a liquid solvent for one or more of the components of the composition and about 0.1 to about 10% by dry/weight of the total composition of clay to increase the adhesiveness of the composition.

2. The composition of claim 1, in which the clay is selective from the group consisting of hydrated aluminum silicate, kaolinite, montmorillonite, atapulgite, illite, bentonite, and halloysite.

3. The composition of claim 2, wherein said adhesive comprises a multipolymer containing vinyl acetate and ethylene monomers, and an acrylic polymer and a natural or synthetic rubber.

4. The composition of claim 3 in which the clay is bentonite.

5. A composition of claim 1 comprising 17-beta-estradiol, a pressure sensitive adhesive, a lower molecular weight glycol and an adhesiveness increasing amount of clay.

6. The transdermal drug delivery device of claim 5 comprising an adhesiveness increasing effective amount of bentonite.

7. The composition of claim 1, comprising 17-beta-estradiol, a multipolymer containing acrylate and ethylene vinyl acetate monomers, a natural or synthetic rubber and a clay.

8. The composition of claim 7 in which the clay is selected from the group consisting of hydrated aluminum silicate, kaolinite, montmorillonite, atapulgite, illite, bentonite, and halloysite.

9. The composition of claim 8, additionally comprising a solvent for the 17-beta-estradiol.

10. The composition of claim 7, which comprises as approximate percent by dry weight, 0.5 to 50% of the drug, 10 to 90% of the multipolymer, 2% to 20% of a rubber, 0.5 to 10% of a clay and 0.5 to 10% of a solvent for the drug.

11. The composition of claim 10 which comprises about 0.5% to about 3% dry weight of a clay.

12. A multi-phase dermal composition comprising a first phase comprising a pressure sensitive adhesive and in admixture therewith, one or more additional phases containing a polymer, 0.1 to 50% by dry weight of the composition of drugs, a solvent for one or more of the components of the composition and about 0.1 to about 10% by dry weight of the composition of clay.

13. The composition of claim 12, in which the clay is selected from the group consisting of hydrated aluminum silicate, kaolinite, montmorillonite, atapulgite, illite, bentonite, and halloysite.

14. The composition of claim 13 which comprises a drug, a multipolymer containing vinyl acetate and ethylene monomers, an acrylic polymer, a natural or synthetic rubber and a glycol.

15. The composition of claim 13, in which the clay is bentonite.

16. The composition of claim 13 in which the clay is present in an amount of from about 0.5 to about 3% by dry weight.

17. The composition of claim 12 in which the clay is present in an amount of from about 0.5 to about 3% by dry weight.

18. The composition of claim 13, in which the drug is 17-beta-estradiol.

19. The composition of claim 14, in which the drug is 17-beta-estradiol.

20. The composition of claim 15, in which the drug is 17-beta-estradiol.

21. The composition of claim 16, in which the drug is 17-beta-estradiol.

22. The composition of claim 17, in which the drug is 17-beta-estradiol.

23. A dermal composition of claim 1, wherein the drug is selected from one or more of the group consisting of an estrogen and nitroglycerin.

24. A dermal composition of claim 1, which is free of water.

25. A dermal composition of claim 12, wherein the drug is selected from the group consisting of an estrogen and nitroglycerin and mixtures thereof.

26. A dermal composition of claim 12, which is free of water.

27. A dermal composition comprising a pressure sensitive adhesive, 0.1 to 50% by dry weight of drug, and about 0.1 to 6% by dry weight of clay to increase the adhesiveness of the composition.

28. A dermal composition of claim 27, wherein the drug is selected from one or more of the group consisting of an estrogen and nitroglycerin.

29. A dermal composition of claim 27, which is substantially free of water.

30. A dermal composition of claim 27, which contains a drug-impermeable backing on a first side of said dermal composition and a protective release liner on a second side which is opposite said first side of said dermal composition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc